Geode Capital Management
HZNP

Geode Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Geode Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,360,567
Closed -$388M – 4819
2023
Q3 		$388M Buy
3,360,567
+83,026
+3% +$8.92M 0.05% 358
2023
Q2 		$337M Buy
3,277,541
+98,488
+3% +$10.4M 0.04% 406
2023
Q1 		$346M Buy
3,179,053
+105,252
+3% +$11.6M 0.05% 384
2022
Q4 		$349M Buy
3,073,801
+54,463
+2% +$4.52M 0.05% 365
2022
Q3 		$187M Buy
3,019,338
+23,963
+0.8% +$1.67M 0.03% 498
2022
Q2 		$239M Sell
2,995,375
-17,320
-0.6% -$1.64M 0.04% 452
2022
Q1 		$317M Buy
3,012,695
+107,397
+4% +$10.5M 0.04% 417
2021
Q4 		$313M Buy
2,905,298
+90,703
+3% +$9.89M 0.04% 434
2021
Q3 		$308M Buy
2,814,595
+6
+0% +$623 0.04% 419
2021
Q2 		$263M Buy
2,814,589
+109,550
+4% +$10.1M 0.04% 444
2021
Q1 		$249M Buy
2,705,039
+89,414
+3% +$7.55M 0.04% 439
2020
Q4 		$191M Buy
2,615,625
+269,175
+11% +$20M 0.03% 474
2020
Q3 		$182M Buy
2,346,450
+117,135
+5% +$8.06M 0.04% 431
2020
Q2 		$124M Buy
2,229,315
+15,284
+0.7% +$654K 0.03% 506
2020
Q1 		$65.6M Buy
2,214,031
+91,168
+4% +$3.08M 0.02% 639
2019
Q4 		$76.8M Buy
2,122,863
+65,694
+3% +$2.01M 0.02% 720
2019
Q3 		$56M Sell
2,057,169
-18,545
-0.9% -$480K 0.01% 823
2019
Q2 		$49.9M Sell
2,075,714
-167,733
-7% -$4.25M 0.01% 870
2019
Q1 		$59.3M Buy
2,243,447
+307,990
+16% +$7.3M 0.02% 752
2018
Q4 		$37.8M Buy
1,935,457
+158,342
+9% +$3.1M 0.01% 872
2018
Q3 		$34.8M Sell
1,777,115
-4,370
-0.2% -$83.1K 0.01% 1024
2018
Q2 		$29.5M Buy
1,781,485
+158,118
+10% +$2.41M 0.01% 1079
2018
Q1 		$23.1M Buy
1,623,367
+110,509
+7% +$1.63M 0.01% 1165
2017
Q4 		$22.1M Buy
1,512,858
+23,950
+2% +$336K 0.01% 1196
2017
Q3 		$18.9M Buy
1,488,908
+66,063
+5% +$840K 0.01% 1285
2017
Q2 		$16.9M Buy
1,422,845
+43,264
+3% +$538K 0.01% 1320
2017
Q1 		$20.4M Buy
1,379,581
+9,476
+0.7% +$153K 0.01% 1130
2016
Q4 		$22.2M Buy
1,370,105
+171,361
+14% +$3.11M 0.01% 1009
2016
Q3 		$21.7M Buy
1,198,744
+93,986
+9% +$1.84M 0.01% 945
2016
Q2 		$18.2M Buy
1,104,758
+272,780
+33% +$4.41M 0.01% 1005
2016
Q1 		$13.8K Buy
831,978
+28,835
+4% +$505K 0.01% 1153
2015
Q4 		$17.4M Buy
803,143
+34,054
+4% +$663K 0.01% 986
2015
Q3 		$15.2M Buy
769,089
+4,398
+0.6% +$139K 0.01% 1056
2015
Q2 		$26.6M Buy
764,691
+300,736
+65% +$9.18M 0.02% 771
2015
Q1 		$12M Buy
463,955
+60,139
+15% +$1.1M 0.01% 1244
2014
Q4 		$5.21M Buy
403,816
+43,073
+12% +$539K ﹤0.01% 1789
2014
Q3 		$4.43M Buy
360,743
+20,348
+6% +$236K ﹤0.01% 1841
2014
Q2 		$5.38M Buy
340,395
+18,455
+6% +$263K ﹤0.01% 1745
2014
Q1 		$4.87M Buy
321,940
+89,810
+39% +$1.01M ﹤0.01% 1792
2013
Q4 		$1.77M Buy
232,130
+27,044
+13% +$146K ﹤0.01% 2377
2013
Q3 		$693K Buy
205,086
+37,972
+23% +$100K ﹤0.01% 2785
2013
Q2 		$411K Buy
+167,114
New +$401K ﹤0.01% 2967

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Geode Capital Management's HZNP Position: Q4 2023 in Review

Geode Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 3,360,567 shares — an estimated $388M sold.

Geode Capital Management first reported a position in HZNP in Q2 2013 and held it in 42 quarters. The position peaked at $388M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Geode Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Geode Capital Management sold 3,360,567 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $388M.
  • Geode Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 42 quarters.
  • Geode Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $388M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Geode Capital Management's 13F filing for Q4 2023, filed 13 Feb 2024.